Michael C. Milone, MD, PhD
Associate Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania
Associate Director, Toxicology Laboratory
University of Pennsylvania Perelman School of Medicine
Contact Information3400 Spruce Street 7103 Founders Pavilion
Philadelphia, PA 19104
Office: 215-662-6575
Fax: 215-662-7529
Email: milone@pennmedicine.upenn.edu
Specialty Division
Laboratory Medicine, Immunobiology and Experimental Pathology
Research Expertise
Research in my laboratory is focused on T cell biology and applications of genetically-engineered T cells to the treatment of disease. Active research projects in my laboratory include:
1) Developing chimeric antigen receptors (CARs) for adoptive immunotherapy of cancer with enhanced function and improved safety.
2) Developing and applying synthetic immunoreceptors to the treatment of immune-mediated disease.
3) Exploring the role of co-stimulatory signals in directing T cell metabolism and the way this metabolism affects T cell function within tumors.
Clinical Expertise
Clinical Laboratory Toxicology, Therapeutic Drug Monitoring, Clinical Chemistry, Blood Banking/Transfusion Medicine, Therapeutic Apheresis
Itmat Expertise
My laboratory is focused upon developing methods to use the immune system to treat cancer. Active research includes 1) exploring the mechanical properties of artificial adhesion substrates used in T cell culture and their influence on T cell biology, 2) development of artificial antigen receptors and signaling systems for control of T cell specificity
Graduate Groups
Cell and Molecular Biology
Education
B.S (Chemical Biology), Stevens Institute of Technology, 1993
Ph.D (Experimental Pathology/ Immunology), UMDNJ - Graduate School of Biomedical Sciences, 1999
M.D. (Medical Doctor), UMDNJ- New Jersey Medical School, 1999
Specialty Certification
Clinical Pathology, American Board of Pathology, 2002
Postgraduate Training
Internship, Internal Medicine, Hospital of the University of Pennsylvania, 1999-2000
Resident, Clinical Pathology, Hospital of the University of Pennsylvania, 2000-2002
Chief Resident, Division of Laboratory Medicine, Hospital of the University of Pennsylvania, 2001-2002
Clinical Fellowship, Blood Banking and Transfusion Medicine, Hospital of the University of Pennsylvania, 2002-2003
Postdoctoral. Research Fellow, Translational Research Program, Abramson Family Cancer Institute, University of Pennsylvania School of Medicine, 2003-2007
Clinical Fellow, Clinical Chemistry and Laboratory Toxicology, Hospital of the University of Pennsylvania, 2004-2007
Awards and Honors
Stanley S. Bergen Award for Academic Excellence, UMDNJ, 1996
Faculty Organization Award, UMDNJ-New Jersey Medical School, 1999
Stanely S. Bergen Medal of Excellence, UMDNJ, 1999
The Peter C. Nowell Teaching Award, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, 2011
Top Ten Clinical Research Achievement Award, Clinical Research Forum, 2017
Memberships and Professional Organizations
American Association of Clinical Chemistry, 2007 - Present
American Society of Clinical Pharmacology and Therapeutics, 2007 - 2010
American Society of Hematology, 2008 - Present
Academy of Clinical Laboratory Physicians and Scientists, 2008 - 2015
College of American Pathologists, 2008 - Present
International Association of Therapeutic Drug Monitoring and Clinical Toxicology, 2009 - Present
American Society of Gene and Cell Therapy, 2009 - Present
American Association of Immunologists, 2009 - Present
American Society of Clinical Pathology, 2015 - Present
National Institute for innovation in Manufacturing Biopharmaceuticals (NIIMBL), 2017 - Present
Web Links
Selected Publications
The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations.
O'Connor Roddy S, Guo Lili, Ghassemi Saba, Snyder Nathaniel W, Worth Andrew J, Weng Liwei, Kam Yoonseok, Philipson Benjamin, Trefely Sophie, Nunez-Cruz Selene, Blair Ian A, June Carl H, Milone Michael C, Scientific reports 8(1): 6289, 2018, PMID:29674640
Neurotoxicity Associated with a High-Affinity GD2 CAR-Response.
Richman Sarah A, Milone Michael C, Cancer immunology research 6(4): 496-497, 2018, PMID:29610424
False-positive results following lentiviral-based tisagenlecleucel therapy with select HIV-1 NAT methods.
Laetsch Theodore W, Maude Shannon L, Milone Michael C, Davis Kara L, Krueger Joerg, Cardenas Ana Maria, Eldjerou Lamis K, Keir Christopher H, Wood Patricia A, Grupp Stephan A, Blood, 2018, PMID:29669777
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.
Garfall Alfred L, Stadtmauer Edward A, Hwang Wei-Ting, Lacey Simon F, Melenhorst Jan Joseph, Krevvata Maria, Carroll Martin P, Matsui William H, Wang Qiuju, Dhodapkar Madhav V, Dhodapkar Kavita, Das Rituparna, Vogl Dan T, Weiss Brendan M, Cohen Adam D, Mangan Patricia A, Ayers Emily C, Nunez-Cruz Selene, Kulikovskaya Irina, Davis Megan M, Lamontagne Anne, Dengel Karen, Kerr Naseem Ds, Young Regina M, Siegel Donald L, Levine Bruce L, Milone Michael C, Maus Marcela V, June Carl H, JCI insight 3(8): , 2018, PMID:29669947
Clinical use of lentiviral vectors.
Milone Michael C, O'Doherty Una, Leukemia, 2018, PMID:29654266
Powered and controlled T-cell production
Michael C. Milone and Bruce L. Levine, Nature Biomedical Engineering 2(): 148-150, 2018
Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma
De-xiu Bu, Reshma Singh, Eugene E. Choi,*, Marco Ruella, Selene Nunez- Cruz, Keith G. Mansfi eld, Paul Bennett, Nathanial Barton, Qilong Wu, Jiquan Zhang, Yongqiang Wang, Lai Wei, Shawn Cogan, Tucker Ezell, Shree Joshi, Kellie J. Latimer, Brian Granda, William R. Tschantz, Regina M. Young, Heather A. Huet, Celeste J. Richardson and Michael C. Milone, Oncotarget In Press(): , 2018
CAR T cell immunotherapy for human cancer
June Carl H, O'Connor Roderick S, Kawalekar Omkar U, Ghassemi Saba and Milone Michael C, Science 359(6382): 1361-1365, 2018, PMID:29567707
The pharmacology of T cell therapies
Vijay Bhoj and Michael C. Milone, Molecular Therapy - Methods & Clinical Development 8(): 210-221, 2018
Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients.
Trofe-Clark Jennifer, Brennan Daniel C, West-Thielke Patricia, Milone Michael C, Lim Mary Ann, Neubauer Robin, Nigro Vincenza, Bloom Roy D, American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017, PMID:29162334
